All News

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

Researchers say findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Adolescents expressed a preference for a combination vaccine covering serogroups A, B, C, W, Y of invasive meningococcal disease, reported researchers.

COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.

Findings underscore the persistence of disparities in meningococcal vaccination coverage in the US, particularly for vaccination against serogroup B.

IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.

Your daily dose of the clinical news you may have missed.

IDWeek 2023: Imagine an intriguing hot topic in infectious disease and you'll find a session or 2 where you can learn more and then choose the next topic, rinse, and repeat.

The monovalent, singe-shot COVID-19 vaccine simplifies what used to be a complicated conversation with patients and stocking the vaccine fridge, too, says Steven Furr, MD.

Your daily dose of the clinical news you may have missed.

A 2-question quiz on the ACIP's recommendations on the new COVID-19 monovalent vaccines that provide protection from currently circulating strains.

Furr on COVID-19 shot: The expectation that 90% of the US population would take this new vaccine that they'd never heard of was probably not practical.

The combination was found equally as effective as 2 standard influenza vaccine comparators and as the Moderna Spikevax COVID-19 booster shot.

Your daily dose of the clinical news you may have missed.

The Novavax COVID-19 vaccine is refreshed with 2023-2024 formula targeting the XBB.1.5 strain.